Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
November 5, 2021
LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of new therapeutic agents based on short interfering ribonucleic acid (siRNA) for the treatment of diseases unmet medical need, announced today that a leading healthcare-focused investment company, Frazier Life Sciences Public Fund, has purchased approximately $ 20 million of existing common stock in Silence and is now a 3% shareholder of the company.
Albert Cha, MD, Ph.D., Managing Partner of Frazier Lif Science, noted: âFrazier Life Sciences is excited about the prospects for Silence’s RNA interference platform technology and the growth potential of the company, given its promising pipeline and the notable success that other companies have demonstrated with RNA interference programs. “
Mark Rothera, President and Cchief Executive Officer of Silence, noted: âFrazier has a history of partnering with science-based healthcare companies, and we are very pleased to welcome them as a significant new shareholder of Silence. This comes at an exciting time for the company as we move forward on two major wholly-owned clinical stage programs and rapidly expand our preclinical pipeline by leveraging our mRNAi GOLD â¢ platform. “
Craig Tooman, Chief Financial Officer of Silence, say: âA key objective of our decision to withdraw from AIM and focus our efforts on the Nasdaq was to attract institutional health funds like Frazier. This is exactly what we envision and we look forward to continuing to expand our shareholder base globally. “
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With over $ 7.1 billion in capital raised, Frazier has invested in more than 200 companies, with types of investment ranging from business start-ups and venture capital to publicly traded companies and buyouts. profitable lower middle market businesses. Based in Menlo Park, Calif., The Frazier Life Sciences team invests globally in private and publicly traded companies that develop and commercialize innovative biopharmaceuticals to meet significant unmet medical needs. Since 2005, 61 companies in the Frazier Life Sciences portfolio, many of which were created or initiated by Frazier, have completed IPOs or mergers and acquisitions. For more information about Frazier Life Sciences, visit their website at www.frazierhealthcare.com/life-sciences.
|Silence Therapeutics plc
Gem Hopkins, Head of International Relations and Corporate Communications
|Phone. : +1 (646) 637-3208|
| Investec Bank plc (Advisor and designated broker)
Daniel Adams / Gary Clarence
|Phone: +44 (0) 20 7597 5970|
Strategic communication of the Consilium
Mary-Jane Elliott / Angela Gray / Chris Welsh
|Phone: +44 (0) 20 3709 5700|
About Silence Therapeutics
Silence Therapeutics is developing a new generation of drugs by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes believed to play a role in the pathology of diseases with high unmet needs. Silence’s proprietary mRNAi GOLD â¢ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, representing a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and widespread unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a) and SLN124 designed to treat conditions of anemia. iron. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
Certain statements made in this announcement are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s clinical and business prospects and timing. planned data reports from testing laboratories. These forward-looking statements are not historical facts but are rather based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as âanticipateâ, âexpectâ, âintendâ, âplanâ, âbelieveâ, âseekâ, âestimateâ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company, are difficult to predict and could cause that actual results differ materially from those expressed or expected. in forward-looking statements, including the risks identified in the Company’s most recent admission document and its amended annual report on Form 20-F filed with the United States Securities and Exchange Commission on April 29, 2021. The Company cautions holders of securities and potential holders of securities not to place undue reliance on these forward-looking statements, which reflect the views of the Company only as of the date of this announcement. The forward-looking statements contained in this announcement relate only to events that occurred on the date on which the statements are made. The Company will not undertake to publicly post revisions or updates to these forward-looking statements to reflect unforeseen events, circumstances or events occurring after the date of this announcement, except as required by law or by any authority. appropriate regulatory framework.